title: We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office.
authors.forename: Gaurav Y
authors.initials: GY
authors.lastname: Shah
authors.forename: Srinivas
authors.initials: S
authors.lastname: Ambatipudi
authors.forename: Merle
authors.initials: M
authors.lastname: Fernandes
authors.forename: Meena
authors.initials: M
authors.lastname: Lakshmipathy
authors.forename: P V K S
authors.initials: PV
authors.lastname: Varma
authors.forename: Virender
authors.initials: V
authors.lastname: Sachdeva
authors.forename: Avinash
authors.initials: A
authors.lastname: Pathengay
mesh_terms: D000556:Ambulatory Surgical Procedures; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D009877:Endophthalmitis / Q000453:epidemiology / Q000209:etiology*; D015818:Eye Infections, Bacterial / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D013203:Staphylococcal Infections / Q000453:epidemiology / Q000209:etiology; D013212:Staphylococcus epidermidis / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000453:epidemiology / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D034363:Viridans Streptococci / Q000302:isolation & purification; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab